# Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

> **NCT04727853** · PHASE2 · COMPLETED · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** irinotecan liposome injection

## Key facts

- **NCT ID:** NCT04727853
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2022-04-26
- **Final completion:** 2022-04-26
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04727853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04727853, "Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04727853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*